News & Updates
Filter by Specialty:
Donanemab BLAZEs through Alzheimer’s treatment TRAIL in first active comparator trial
The first study to directly compare two disease-modifying agents for Alzheimer’s disease (AD), the phase III TRAILBLAZER-ALZ 4 study shows promising efficacy and safety data on donanemab vs aducanumab for the treatment of early symptomatic AD.
Donanemab BLAZEs through Alzheimer’s treatment TRAIL in first active comparator trial
10 May 2023
Intranasal zavegepant offers rapid pain relief in patients with migraine
Treatment with zavegepant nasal spray provides pain and symptom relief in patients with migraine, according to a recent US study presented at AAN 2023.
Intranasal zavegepant offers rapid pain relief in patients with migraine
10 May 2023
Mid-dose beta-blocker therapy tied to highest mortality reduction after AMI
Use of any beta-blocker dose results in a significant decrease in mortality following acute myocardial infarction (AMI) when compared with no treatment, reports a study. Doses >25 percent to 50 percent of the currently recommended target dose (RTD) are associated with highest mortality reduction within the first year after AMI, indicating that higher doses are not required.
